drugset
drugset / Trial / NCT03795441

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

NCT03795441 ↗

Phase 1 Completed 24 enrolled Janssen Vaccines & Prevention B.V.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the shedding and kinetics of the Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) vaccine after one intramuscular injection of Ad26.RSV.preF in adults.

Timeline

Start
2019-01-07
Primary completion
2019-07-28
Completion
2019-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.RSV.preF Vaccine — Intramuscular

Indications

No indication recorded.